Cargando…

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

BACKGROUND: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens. This study aimed to evaluate the in vitro activity of ceftolozane–tazobactam against clinical bacterial isolat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuon, Felipe Francisco, Cieslinski, Juliette, Rodrigues, Suellen da Silva, Serra, Fernando Brandão, Paula, Marina Della-Negra de
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392040/ https://www.ncbi.nlm.nih.gov/pubmed/32360070 http://dx.doi.org/10.1016/j.bjid.2020.04.004

Ejemplares similares

Activity of ceftolozane-tazobactam and comparators against gram-negative bacilli: Results from the study for monitoring antimicrobial resistance trends (SMART – Brazil; 2016–2017)
por: Beirão, Elisa Maria, et al.
Publicado: (2020)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study
por: Belkhair, J., et al.
Publicado: (2021)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

Evaluation of in vitro activity of ceftolozane/tazobactam and comparators against recent clinical bacterial isolates, and genomics of Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli isolates that demonstrated resistance to ceftolozane/tazobactam: data from Kuwait and Oman
por: Alfouzan, Wadha, et al.
Publicado: (2022)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
por: Wang, Li-Ting, et al.
Publicado: (2021)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

841. Frequency of carbapenemase-encoding genes among Imipenem-Resistant Gram-negative Bacilli isolated from Latin America: Is there a Role for Imipenem/Relebactam? Results from SMART 2017-2018
por: Gales, Ana Cristina, et al.
Publicado: (2020)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess
por: Lewis, Paul O., et al.
Publicado: (2018)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
por: Pezzi, Mario, et al.
Publicado: (2019)

Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020)

Real-world use of ceftolozane/tazobactam: a systematic literature review
por: Puzniak, Laura, et al.
Publicado: (2021)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
por: Khankhel, Z. S., et al.
Publicado: (2022)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections
por: Chandorkar, Gurudatt, et al.
Publicado: (2015)

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
por: Hong, Mai-Chi, et al.
Publicado: (2013)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
por: Skalweit, Marion J
Publicado: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
por: Jolliff, Jeffrey C., et al.
Publicado: (2016)

2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
por: Cabrera, Nicolo, et al.
Publicado: (2019)

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review
por: Telles, João Paulo, et al.
Publicado: (2019)

1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam Real World Analysis)
por: Soriano, Alex, et al.
Publicado: (2020)

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
por: Kauf, Teresa L, et al.
Publicado: (2017)

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2021)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
por: Li, Junjie, et al.
Publicado: (2020)

Vancomycin trough level and loading dose
por: Tuon, Felipe Francisco, et al.
Publicado: (2018)

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates
por: Forrester, Jeanne B, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r872kt161qa1kmg6jfva9jgikj